Bipolar Disorder
📧 Sign up to get email alerts when something new happens for Bipolar Disorder.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2013-03-06FDA Approved: TEGRETOL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Tegretol (carbamazepine) filed by Novartis Pharmaceuticals Corporation. The supplemental act…
-
FDA approval · 2013-03-06FDA Approved: TEGRETOL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tegretol (carbamazepine) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2013-03-01FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for GEODON (ziprasidone mesylate) submitted by Viatris Specialty LLC.
-
FDA approval · 2013-03-01FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for GEODON (ziprasidone) submitted by Viatris Specialty LLC.
-
FDA approval · 2013-02-27FDA Approved: DEPAKOTE — Supplemental Application (AbbVie Inc.)
The FDA approved AbbVie's supplemental application for DEPAKOTE (divalproex sodium), updating regulatory labeling as part of the supplementa…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-02-25Clinical Trial Update: Relative Effectiveness of Schizophrenia Therapy Study
This clinical trial studying the relative effectiveness of schizophrenia therapy has completed. The study also includes bipolar disorder amo…
-
CLINICAL_TRIALS trial_result · 2013-02-22Clinical Trial Update: Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
This update reports results from a youth-focused trial evaluating the effectiveness and tolerability of a second-generation antipsychotic ac…
-
CLINICAL_TRIALS research · 2013-02-20Clinical Trial Update: The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy
Clinical trial update assessing antiatherogenic properties of HDL in psychiatric patients, comparing those with and without antipsychotic th…
-
CLINICAL_TRIALS trial_result · 2013-02-18Clinical Trial Update: A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression [Phase 4]
A Phase 4 clinical trial in adolescents (ages 10-17) with bipolar depression has completed. Results were posted in 2013.
-
CLINICAL_TRIALS trial_result · 2013-02-15Clinical Trial Update: Study Evaluating Bifeprunox in Bipolar Depression [Phase 3]
A Phase 3 trial evaluating Bifeprunox for bipolar depression has completed; sponsor Wyeth/Pfizer provided an update.
-
FDA approval · 2013-02-12FDA Approved: QUETIAPINE — Original Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories' generic quetiapine fumarate under an original ANDA, making a generic version of quetiapine available.
-
CLINICAL_TRIALS trial_result · 2013-02-08Clinical Trial Update: A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder [Phase 4]
A Phase 4 neuroimaging study examining brain activity in major depressive disorder and bipolar disorder has completed.
-
CLINICAL_TRIALS trial_result · 2013-02-04Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder [Phase 3]
Phase 3 trial evaluated the efficacy and safety of adding aripiprazole to lithium or valproate for mania in Bipolar I Disorder; the study is…
-
CLINICAL_TRIALS trial_result · 2013-01-28Clinical Trial Update: Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients [Phase 4]
Phase 4 trial comparing add-on valproate therapy to quetiapine monotherapy in acutely manic bipolar disorder patients; the study was termina…
-
CLINICAL_TRIALS withdrawal · 2013-01-23Clinical Trial Update: A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder [Phase 3]
Phase 3 trial of ramelteon tablets for sublingual administration (TAK-375SL) in maintenance treatment of Bipolar I disorder has been withdra…
-
FDA approval · 2013-01-18FDA Approved: LAMOTRIGINE EXTENDED RELEASE — Original Application (Par Health USA, LLC)
The FDA approved Par Health USA, LLC's Lamotrigine Extended Release as a new generic product under an original ANDA.
-
CLINICAL_TRIALS trial_result · 2013-01-04Clinical Trial Update: Seroquel in Bipolar Depression Versus Lithium [Phase 3]
A Phase 3 study comparing quetiapine (Seroquel) to lithium in bipolar depression has completed.
-
CLINICAL_TRIALS trial_result · 2013-01-04Clinical Trial Update: Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder [Phase 3]
Phase 3 trial evaluating the efficacy and safety of quetiapine fumarate (SEROQUEL) for treating alcohol dependence in patients with bipolar …
-
CLINICAL_TRIALS trial_result · 2013-01-04Clinical Trial Update: Seroquel in Bipolar Depression Versus SSRI [Phase 3]
A Phase 3 trial evaluating quetiapine (Seroquel) for bipolar depression, comparing it to an SSRI, has completed.
-
CLINICAL_TRIALS trial_result · 2013-01-04Clinical Trial Update: Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania [Phase 3]
A Phase 3 trial comparing quetiapine fumarate (SEROQUEL) to placebo in children and adolescents with Bipolar I disorder has completed.
-
CLINICAL_TRIALS trial_result · 2013-01-04Clinical Trial Update: Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression [Phase 3]
Phase 3, controlled study evaluating quetiapine fumarate in bipolar depression has been completed.
-
FDA approval · 2012-12-31FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved Teva's supplemental application for a generic olanzapine and fluoxetine product. This expands access to the olanzapine/fluo…
-
FDA approval · 2012-12-31FDA Approved: RISPERIDONE — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved a supplemental application for risperidone from Ajanta Pharma USA Inc., enabling a new generic risperidone product.
-
FDA approval · 2012-12-26FDA Approved: LAMOTRIGINE EXTENDED-RELEASE — Original Application (Par Health USA, LLC)
The FDA approved Par Health USA, LLC's Lamotrigine Extended-Release as an original-application generic, to be marketed for the approved epil…
-
CLINICAL_TRIALS trial_result · 2012-12-21Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1) [Phase 1]
Phase 1 study evaluating pharmacokinetics, safety and tolerability of sublingual asenapine in pediatric patients with schizophrenia or Bipol…